Lv11
88 积分 2022-07-22 加入
Post-progression treatment options after CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer
9天前
已完结
Proteomics-Driven Strategies for Proximity-Inducing Drug Discovery
1个月前
已完结
Cancer burden and control in China: landscape, trends and challenges
1个月前
已完结
Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer
1个月前
已完结
A High-Potency Protein That Normalizes Body Weight in DIO Mice through Triple Agonism at FGF21, GLP1, and GIP Receptors
4个月前
已完结
Precision Oncology: 2025 in Review
7个月前
已完结
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
8个月前
已完结
Mapping the effectiveness and risks of GLP-1 receptor agonists
8个月前
已完结
The non-small-cell lung cancer drug market
8个月前
已完结
A rapid imaging-based screen for induced-proximity degraders identifies a potent degrader of oncoprotein SKP2
10个月前
已完结
皖公网安备34019202002308
